Aclaris Therapeutics Announces Exclusive, Global License Agreement With Biosion, Inc., Adding Potential Best-in-Class Biologics Assets to Pipeline

GlobeNewswireNov 18 08:10 ET

Aclaris Therapeutics Upgraded to Buy From Neutral at BTIG

TipRanks21:30 ET · Ratings

Aclaris Therapeutics Analyst Ratings

Benzinga16:28 ET · Ratings

Aclaris Therapeutics Shares Spike Higher; Piper Sandler Upgrads Stock To Overweight With $13 Target Following Biosion Deal; Highlights Pipeline For Atopic Dermatitis And I&I Market, Catalysts Expected In 2025 Trials

Benzinga15:08 ET

Express News | Biosion- to Receive Over $40 Million Cash Payment and 19.9% Aclaris Shares

ReutersNov 18 08:51 ET

Biosion Announces Exclusive, Global License Agreement With Aclaris Therapeutics on Two Potential First-in-Class and Best-in-Class Immunology Assets

PR NewswireNov 18 08:50 ET